Immünoglobülin A Vasküliti (Henoch-Schönlein Purpura) Tanısı Olan Çocuk Hastalarda Artmış Ailevi Akdeniz Ateşi Sıklığı

Yıl 2018, Cilt: 16 Sayı: 1, 35 - 46, 01.04.2018

Hafize Emine Sönmez Ezgi Deniz Batu Yelda Bilginer

Öz

GİRİŞ ve AMAÇ: İmmunoglobülin A vasküliti çocukluk çağının en sık vaskülitidir. Trombositopenik
olmayan purpura, karın ağrısı, gastrointestinal kanama, artrit veya artralji ve nefrit ile karakterizedir.
Ailevi Akdeniz ateşi (AAA) ise en sık görülen otoinflamatuvar hastalık olup, tekrarlayan ateş ve serozit
atakları hastalığın temel özellikleridir. Çalışmamızda kliniğimizde IgAV/HSP tanısı ile takipli olan
olguların genel özelliklerini, MEFV mutasyon sıklığını tespit etmeyi, AAA+IgAV/HSP olan olgularla
sadece IgAV/HSP olan olguların klinik, laboratuvar ve tedavi özelliklerini karşılaştırmayı amaçladık.

GEREÇ ve YÖNTEMLER: Çalışmaya 2014-2016 yılları arasında IgAV/HSP tanısı almış olan 159
olgudan MEFV analizi yapılmış olan 114 olgu dâhil edildi. IgAV/HSP tanısı ile takipli olguların geriye
dönük olarak MEFV mutasyon sonuçları, demografik, klinik özellikleri ve tanı anındaki laboratuvar
bulguları kaydedildi. Ayrıca IgAV/HSP+AAA tanısı olan hastalar ile sadece IgAV/HSP olan hastalar
karşılaştırıldı.

BULGULAR: 88 olguda MEFV mutasyonu tespit edilmedi. 26 (%22,9) olgunun ise 9’u M694V/-
(%7,9), 6’sı M694V/M694V (%5,3), 3’ü M680I/- (%2,6),3’ü V726A/- (%2,6), 2’si E148Q/- (%1,8),
biri M694V/M680I (%0,9), A744S/- (%0,9), biri ise R761H/- (%0,9) idi. 9 olguda (%7,9) AAA tanısı
mevcuttu. IgAV/HSP+AAA hastalarında medyan CRP değerinin ve nonsteroidal anti-inflamatuvar ilaç
(NSAİİ) ve kolşisin tedavisi alma oranının daha yüksek olduğu saptandı.

TARTIŞMA ve SONUÇ: Çalışmamızda IgAV/HSP+AAA olan olgularda, IgAV/HSP sürecinde
hastaların CRP değerlerinin daha yüksek ve NSAİİ ihtiyacının daha sık olabileceğini gözlemledik.
IgAV/HSP tanısı ile takipli olan olgularda MEFV mutasyon varlığının gösterilmesi erken tanı ve etkin
inflamasyon kontrolü ile olası komplikasyonların önüne geçilmesine yardımcı olabilir.

ABSTRACT

INTRODUCTION: Immunoglobulin A vasculitis/Henoch Schönlein purpura (IgAV/HSP) is the most
common vasculitis in childhood. It is characterized by non-thrombocytopenic purpura, abdominal pain,
gastrointestinal bleeding, arthritis or arthralgia and nephritis. Familial Mediterranean fever (FMF), is
the most common autoinflammatory disease, manifesting with recurrent fever episodes and serositis. In
this study, we aimed to determine the general characteristics and MEFV (Mediterranean FeVer) mutation
occurrence rate in patients diagnosed with IgAV/HSP and to compare the clinical, laboratory and
treatment characteristics of cases with FMF+IgAV/HSP and cases with only IgAV/HSP.
METHODS: A total of 114 cases analyzed for MEFV out of 159 cases diagnosed with IgAV/HSP
between the years 2014-2016 were included in the study. MEFV gene analysis, demographic, clinical,
and laboratory findings were retrospectively recorded. In addition, patients with AAA and only IgAV /
HSP cases were compared.

RESULTS: The MEFV mutation was not detected in 88 cases. 9 of the 26 (22.9%) cases were M694V/-
(7.9%), 6 were M694V/M694V (5.3%), 3 were M680I/- (2.6%), 3 were V726A/- (2.6%), 2 were
E148Q/- (1.8%), one was M694V/M680I (0.9%) and one was R761H/- (0.9%). 9 cases (7.9%) were
diagnosed with FMF. The median C-reactive protein (CRP) value was higher in IgAV/HSP+FMF
patients and they had a higher rate of using nonsteroidal anti-inflammatory drugs (NSAIDs) and
colchicine treatment.

DISCUSSION and CONCLUSION: Patients with IgAV/HSP+FMF had higher CRP levels and needed
NSAIDs more frequently during the course of IgAV/HSP. Demonstrating the presence of the MEFV
mutation in cases diagnosed with IgAV/HSP may help to prevent possible complications through early
diagnosis and effective control of inflammation.

Key words: Immunoglobulin A vasculitis / Henoch Schönlein purpura; familial Mediterranean fever; 

Anahtar Kelimeler

immunglobulin A vasküliti, Henoch Schönlein purpurası, ailevi Akadeniz ateşi

Kaynakça

• 1. Batu ED, Ozen S. Pediatric vasculitis. Cur Rheumatol Rep 2012;14:121-9.
• 2. Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. 2010. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheumatic Dis 2010;69:798-806.
• 3. Ozen S, Bakkaloglu A, Dusunsel R, Soylemezoglu O, Ozaltin F, Poyrazoglu H, et al. Childhood vasculitides in Turkey: a nationwide survey. Clin Rheumatol 2007;26:196-200.
• 4. Ozdogan H, Arisoy N, Kasapcapur O, Sever L, Caliskan S, Tuzuner N, et al. Vasculitis in familial Mediterranean fever. J Rheumatol 1997;24:323-7.
• 5. Dogan CS, Akman S, Koyun M, Bilgen T, Comak E, Gokceoglu AU. Prevalence and significance of the MEFV gene mutations in childhood Henoch-Schonlein purpura without FMF symptoms. Rheumatol Int 2013;33:377-80.
• 6. Yalcinkaya F, Ozen S, Ozcakar ZB, Aktay N, Cakar N, Düzova A, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 2009;48:395-8.
• 7. Ozen S, Batu ED. The myths we believed in familial Mediterranean fever: what have we learned in the past years? Semin Immunopathol 2015;37:363-9.
• 8. Yalcinkaya F, Ozcakar ZB, Kasapcopur O, Ozturk A, Akar N, Bakaloğlu A, et al. Prevalence of the MEFV gene mutations in childhood polyarteritis nodosa. J Pediatr 2007;151:675-8.
• 9. Ozen S, Bakkaloglu A, Yilmaz E, Duzova A, Balci B, Topaloglu R, et al. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? J Rheumatol 2003;30:2014-8.. 10. Bayram C, Demircin G, Erdogan O, Bulbul M, Caltik A, Akyuz SG. Prevalence of MEFV gene mutations and their clinical correlations in Turkish children with Henoch-Schonlein purpura. Acta Paediatr 2011;100:745-9.
• 11. Yilmaz E, Ozen S, Balci B, Duzova A, Topaloglu R, Besbaş N, et al. Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 2001;9:553-5.
• 12. Ozcakar ZB, Yalcinkaya F, Cakar N, Acar B, Kasapcopur O, Ugüten D, et al. MEFV mutations modify the clinical presentation of Henoch-Schonlein purpura. J Rheumatol 2008;35:2427-9.
• 13. Ozen S. Vasculopathy, Behcet's syndrome, and familial Mediterranean fever. Curr Opin Rheumatol 1999;11:393-8.
• 14. Gershoni-Baruch R, Broza Y, Brik R. Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schonlein purpura. J Pediatr 2003;143:658-61.
• 15. Chae JJ, Komarow HD, Cheng J, Wood G, Raben N, Liu PP, et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003;11:591-604.
• 16. Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A 2006;103:9982-7.
• 17. Olgun A, Akman S, Kurt I, Tuzun A, Kutluay T. 2005. MEFV mutations in familial Mediterranean fever: association of M694V homozygosity with arthritis. Rheumatol Int 2005;25:255-9.
• 18. Allali S, Fraitag S, Terrier B, Bodemer C, Chalumeau M. Efficacy of colchicine in a child with relapsing bullous Henoch-Schonlein purpura. Eur J Pediatr 2016;175:147-9.
• 19. Saulsbury FT. 2009. Successful treatment of prolonged Henoch-Schonlein purpura with colchicine. Clin Pediatr (Phia) 2009;48:866-8.
• 20. Giancane G, Ter Haar NM, Wulffraat N, Vastert SJ, Barron K, Hentgen V, et al. Evidencebased recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis 2015;74:635-41.